Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2008 1
2010 1
2011 1
2014 1
2016 1
2017 4
2018 4
2019 5
2020 3
2021 2
2022 3
2023 6
2024 8
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Free PMC article. Clinical Trial.
Split decision.
Giridhar KV, Dhaliwal G, Tierney L. Giridhar KV, et al. J Gen Intern Med. 2014 Dec;29(12):1707-10. doi: 10.1007/s11606-014-2874-1. J Gen Intern Med. 2014. PMID: 24913002 Free PMC article. No abstract available.
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
Yonemori K, Boni V, Min KG, Meniawy TM, Lombard J, Kaufman PA, Richardson DL, Bender L, Okera M, Matsumoto K, Giridhar KV, García-Sáenz JA, Prenen H, de Speville Uribe BD, Dizon DS, Garcia-Corbacho J, Van Nieuwenhuysen E, Li Y, Estrem ST, Nguyen B, Bacchion F, Ismail-Khan R, Jhaveri K, Banda K. Yonemori K, et al. Among authors: giridhar kv. Gynecol Oncol. 2024 Dec;191:172-181. doi: 10.1016/j.ygyno.2024.10.006. Epub 2024 Oct 22. Gynecol Oncol. 2024. PMID: 39442371 Free article. Clinical Trial.
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
Haddad TC, Suman VJ, D'Assoro AB, Carter JM, Giridhar KV, McMenomy BP, Santo K, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs CJ, Oh SY, Clark AS, Mayer IA, Keyomarsi K, Hobday TJ, Peethambaram PP, O'Sullivan CC, Leon-Ferre RA, Liu MC, Ingle JN, Goetz MP. Haddad TC, et al. Among authors: giridhar kv. JAMA Oncol. 2023 Jun 1;9(6):815-824. doi: 10.1001/jamaoncol.2022.7949. JAMA Oncol. 2023. PMID: 36892847 Free PMC article. Clinical Trial.
Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer.
Leon-Ferre RA, Whitaker KR, Suman VJ, Hoskin T, Giridhar KV, Moore RM, Al-Jarrad A, McLaughlin SA, Northfelt DW, Hunt KN, Conners AL, Moyer A, Carter JM, Kalari K, Weinshilboum R, Wang L, Ingle JN, Knutson KL, Ansell SM, Boughey JC, Goetz MP, Villasboas JC. Leon-Ferre RA, et al. Among authors: giridhar kv. Breast Cancer Res. 2024 Jun 10;26(1):97. doi: 10.1186/s13058-024-01848-z. Breast Cancer Res. 2024. PMID: 38858721 Free PMC article.
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC).
Huppert LA, Mahtani R, Fisch S, Dempsey N, Premji S, Raimonde A, Jacob S, Quintal L, Melisko M, Chien J, Sandoval A, Carcas L, Ahluwalia M, Harpalani N, Hoppenworth J, Blaes A, Blum K, Kim MO, Idossa D, Rao R, Giridhar KV, Rugo HS. Huppert LA, et al. Among authors: giridhar kv. NPJ Breast Cancer. 2025 Apr 15;11(1):34. doi: 10.1038/s41523-025-00748-5. NPJ Breast Cancer. 2025. PMID: 40234477 Free PMC article.
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis.
Janni W, Friedl TWP, Yab TC, Bidard FC, Cristofanilli M, Hayes DF, Ignatiadis M, Regan MM, Alix-Panabieres C, Barlow WE, Caldas C, Carey LA, Dirix L, Fehm T, Garcia-Saenz JA, Gazzaniga P, Generali D, Gerratana L, Gisbert-Criado R, Jacot W, Jiang Z, Joosse SA, Lianidou E, López López R, Magbanua MJM, Manso L, Mavroudis D, Müller V, Munzone E, Pantel K, Pierga JY, Rack B, Riethdorf S, Rugo HS, Sideras K, Sleijfer S, Smerage J, Stebbing J, Terstappen LWMM, Vidal-Martínez J, Wallwiener M, Giridhar KV, Liu MC. Janni W, et al. Among authors: giridhar kv. Clin Cancer Res. 2025 Jun 3;31(11):2196-2209. doi: 10.1158/1078-0432.CCR-24-3108. Clin Cancer Res. 2025. PMID: 40100138 Free PMC article.
42 results